Informations générales (source: ClinicalTrials.gov)
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer (LIBERTYLUNG)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
mai 2021
juin 2028
30 juillet 2024
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and
eligible for first-line treatment with immune checkpoint inhibitor. Combination with
chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA
follow-up.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/12/2024 12:44:18 | Contact (sur clinicalTrials) | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 04/12/2024 12:44:04 | Contact (sur clinicalTrials) | |||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Ambroise Paré | Etienne GIROUX LE PRIEUR, PR | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Histologically-proven NSCLC.
2. Age ≥ 18 years.
3. Advanced or metastatic stage IV.
4. Treatment-naïve patient.
5. Eligibility to first-line treatment with immune checkpoint inhibitor.
6. Measurable disease according to RECIST 1.1 criteria on CT-Scan.
7. Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor
biopsy.
8. No ALK or EGFR gene alteration.
9. Availability of tumor tissue for NGS analysis (7 slides).
10. PS 0 or 1.
11. Signed informed consent of the patient.
1. Histologically-proven NSCLC.
2. Age ≥ 18 years.
3. Advanced or metastatic stage IV.
4. Treatment-naïve patient.
5. Eligibility to first-line treatment with immune checkpoint inhibitor.
6. Measurable disease according to RECIST 1.1 criteria on CT-Scan.
7. Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor
biopsy.
8. No ALK or EGFR gene alteration.
9. Availability of tumor tissue for NGS analysis (7 slides).
10. PS 0 or 1.
11. Signed informed consent of the patient.
1. No social security affiliation.
2. Person under legal protection.
3. Pregnant and breastfeeding women.
Patients can participate to another clinical trial that is not modifying immunotherapy or
immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's
information